Clinical Trial Update: Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and expansion study of intratumoral mRNA-2752 in advanced malignancies has completed, with expansion cohorts in several indications incl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-hodgkin Lymphoma
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• mRNA-2752

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma | Phase 1 | Status: COMPLETED